Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
Rising ovarian and uterine cancer rates are linked to high BMI, with disparities across sociodemographic index levels, particularly in low- and middle-SDI regions. Sarcopenia is prevalent in ...
Scientists have discovered that key compounds from cannabis—CBD and THC—show surprisingly strong effects against ovarian cancer cells. Used together, they slow cell growth, reduce colony formation, ...
Share on Pinterest Cannabis derivatives may lead to new treatments for ovarian cancer. Image Credit: Bloomberg Creative Photos/Getty Images Early lab research shows that two cannabis compounds, THC ...
"Ovarian cancer remains one of the deadliest gynecological malignancies, characterized by late diagnosis, high recurrence rates, and limited effective treatment options," said Dr. Siyao Tong of Khon ...
Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ovarian cancer diagnosis this year. Fan's team at The University of New ...
Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments.
NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Ovarian Cancer Research Alliance (OCRA) today announced the launch of its Center for Public Policy, a dedicated hub that reflects expanded policy priorities ...
Diane Davis thought a diagnosis of advanced ovarian cancer was the answer she had been looking for. For months, she had been sick. Antibiotics were no help. When she went to the emergency room, a CT ...
READY TO LACE UP YOUR SHOES AND WALK TO HELP SAVE LIVES. THE NATIONAL OVARIAN CANCER COALITION IS HOSTING ITS ANNUAL TOGETHER IN TEAL WALK NEXT WEEKEND, AND WE ARE SO EXCITED TO HAVE BOTH OF THESE ...
JSKN003 has shown a 63% objective response rate and 7.7 months median progression-free survival in PROC patients, with higher efficacy in HER2-positive subgroups. The FDA's fast track designation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback